Asaad Jandali, MD
Pulmonary Disease · Munster, INNPI 1649240276
Payments from drug & device makers
Across 1,194 payments — averaging $134.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$92K
- Regeneron Healthcare Solutions, Inc.$19K
- Viatris Specialty LLC$10K
- Intuitive Surgical$8K
- Penumbra, Inc.$4K
- Verona Pharma, Inc.$4K
- plus $24K from 54 others
What the payments were for
- Consulting fees$27,78117%
- Speaking & faculty fees$89,37556%
- Travel & lodging$13,0808%
- Food & beverage$24,83015%
- Education$5,7994%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$96,253
- DUPIXENT$17,774
- Da Vinci Surgical System$7,291
- Indigo System$4,388
- Ohtuvayre$3,928
- MONARCH$1,171
- Spin$1,123
- Monarch Platform$994
- CT THROMBECTOMY SYSTEM KIT$723
- FLOWTRIEVER CATHETER, S$723
- Impella$494
- DA VINCI SP$297
- Inspire$287
- HemoSphere$200
- Inspire Upper Airway Stimulation System$176
- PASCAL$150
- ALIYA SYSTEM$136
- PURIFIED CORTROPHIN GEL$133
- VYNDAQEL$125
- SUNOSI$121
How this compares
$160,865 in reported general payments places this provider in the 95th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 356 | $429,108 |
| OfevNintedanib Esylate | 25 | $331,466 |
| Breo ElliptaFluticasone/Vilanterol | 232 | $164,047 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 174 | $160,205 |
| OpsumitMacitentan | 12 | $131,083 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $82,737 |
| NucalaMepolizumab | 19 | $65,447 |
| Spiriva RespimatTiotropium Bromide | 54 | $54,282 |
| Dupixent SyringeDupilumab | 13 | $47,656 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 39 | $35,645 |
| XareltoRivaroxaban | 32 | $33,483 |
| XolairOmalizumab | 12 | $32,942 |
| Incruse ElliptaUmeclidinium Bromide | 51 | $29,773 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,100 | $23,964 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $21,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta | $2,334 | $853,205849 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $818 | $442,936144 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $708 | $131,08312 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,725 | $95,358123 claims |
| Johnson & JohnsonXarelto | $2,955 | $33,48332 claims |
| PfizerEliquis | $322 | $10,42718 claims |
| MerckDulera | $102 | $6,82912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Munster
- Fadi LayousMunster$64K
- Bassem SrourMunster$16K
- Wassim ShwaikiMunster$16K
- Cynthia BrownIndianapolis$7.3M
- Imad ShawaGreenwood$1.4M
- David MaresAnderson$1.3M
- Raja DevanathanHobart$862K
- Olusegun ApataGary$780K
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.